Maarten C Bosland1, Erika Enk1, Joanne Schmoll2, Michael J Schlicht1, Carla Randolph2, Ryan J Deaton1, Hui Xie3, Anne Zeleniuch-Jacquotte2, Ikuko Kato2,4. 1. Department of Pathology, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA. 2. Department of Environmental Medicine, New York University School of Medicine, New York, NY, USA. 3. Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, IL, USA. 4. Departments of Oncology and Pathology, Wayne State University, Detroit, MI, USA.
Abstract
BACKGROUND: Many studies have addressed effects of dietary supplementation with soy protein, but most have been inconsistent and few have been long-term studies in men. OBJECTIVES: This study was a secondary analysis of body weight, blood pressure, thyroid hormones, iron status, and clinical chemistry in a 2-y trial of soy protein supplementation in middle-aged to older men. METHODS: Data were analyzed as secondary outcomes of a randomized controlled trial of dietary supplementation with 20 g/d soy protein isolate, providing 41 mg/d total isoflavones and 23 mg/d genistein, in 44- to 75-y-old men who were at risk of cancer recurrence following prostatectomy randomized to soy (n = 50) or a casein-based placebo (n = 43). Weight, blood pressure, and blood samples were collected at baseline, every 2 mo in year 1, and every 3 mo in year 2. RESULTS: Compared with casein, soy supplementation did not affect body weight, blood pressure, serum total cholesterol, calcium, phosphorus, and thyroid hormones. Serum ferritin concentrations doubled over 2 y in both groups (117-129%), whereas hemoglobin and hematocrit increased slightly. In an exploratory subgroup analysis of soy group data, weight increased in subjects producing equol but not in nonproducers. Blood pressure was reduced in nonequol producers but not in producers. Other endpoints were not affected by equol production status. CONCLUSIONS: Soy protein supplementation for 2 y compared with a casein-based placebo did not affect body weight, blood pressure, serum total cholesterol, iron status parameters, calcium, phosphorus, and thyroid hormones. Exploratory analysis suggests that equol production status of subjects on soy may modify effects of soy on body weight and possibly blood pressure. This trial was registered at clinicaltrials.gov as NCT00765479.
BACKGROUND: Many studies have addressed effects of dietary supplementation with soy protein, but most have been inconsistent and few have been long-term studies in men. OBJECTIVES: This study was a secondary analysis of body weight, blood pressure, thyroid hormones, iron status, and clinical chemistry in a 2-y trial of soy protein supplementation in middle-aged to older men. METHODS: Data were analyzed as secondary outcomes of a randomized controlled trial of dietary supplementation with 20 g/d soy protein isolate, providing 41 mg/d total isoflavones and 23 mg/d genistein, in 44- to 75-y-old men who were at risk of cancer recurrence following prostatectomy randomized to soy (n = 50) or a casein-based placebo (n = 43). Weight, blood pressure, and blood samples were collected at baseline, every 2 mo in year 1, and every 3 mo in year 2. RESULTS: Compared with casein, soy supplementation did not affect body weight, blood pressure, serum total cholesterol, calcium, phosphorus, and thyroid hormones. Serum ferritin concentrations doubled over 2 y in both groups (117-129%), whereas hemoglobin and hematocrit increased slightly. In an exploratory subgroup analysis of soy group data, weight increased in subjects producing equol but not in nonproducers. Blood pressure was reduced in nonequol producers but not in producers. Other endpoints were not affected by equol production status. CONCLUSIONS: Soy protein supplementation for 2 y compared with a casein-based placebo did not affect body weight, blood pressure, serum total cholesterol, iron status parameters, calcium, phosphorus, and thyroid hormones. Exploratory analysis suggests that equol production status of subjects on soy may modify effects of soy on body weight and possibly blood pressure. This trial was registered at clinicaltrials.gov as NCT00765479.
Authors: K Higashi; S Abata; N Iwamoto; M Ogura; T Yamashita; O Ishikawa; F Ohslzu; H Nakamura Journal: J Nutr Sci Vitaminol (Tokyo) Date: 2001-08 Impact factor: 2.000
Authors: Helena J Teede; Dimitra Giannopoulos; Fabien S Dalais; Jonathan Hodgson; Barry P McGrath Journal: J Am Coll Nutr Date: 2006-12 Impact factor: 3.169
Authors: S Hüser; S Guth; H G Joost; S T Soukup; J Köhrle; L Kreienbrock; P Diel; D W Lachenmeier; G Eisenbrand; G Vollmer; U Nöthlings; D Marko; A Mally; T Grune; L Lehmann; P Steinberg; S E Kulling Journal: Arch Toxicol Date: 2018-08-21 Impact factor: 5.153
Authors: B J Macfarlane; W B van der Riet; T H Bothwell; R D Baynes; D Siegenberg; U Schmidt; A Tal; J R Taylor; F Mayet Journal: Am J Clin Nutr Date: 1990-05 Impact factor: 7.045
Authors: Maarten C Bosland; Ikuko Kato; Anne Zeleniuch-Jacquotte; Joanne Schmoll; Erika Enk Rueter; Jonathan Melamed; Max Xiangtian Kong; Virgilia Macias; Andre Kajdacsy-Balla; L H Lumey; Hui Xie; Weihua Gao; Paul Walden; Herbert Lepor; Samir S Taneja; Carla Randolph; Michael J Schlicht; Hiroko Meserve-Watanabe; Ryan J Deaton; Joanne A Davies Journal: JAMA Date: 2013-07-10 Impact factor: 56.272
Authors: Sonia Blanco Mejia; Mark Messina; Siying S Li; Effie Viguiliouk; Laura Chiavaroli; Tauseef A Khan; Korbua Srichaikul; Arash Mirrahimi; John L Sievenpiper; Penny Kris-Etherton; David J A Jenkins Journal: J Nutr Date: 2019-06-01 Impact factor: 4.798
Authors: Kenneth F Adams; Chu Chen; Katherine M Newton; John D Potter; Johanna W Lampe Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-04 Impact factor: 4.254